RevenueNet IncomeP/EP/SEBITDividendStocksMarket capitalizationDebtLiabilitiesEquityAAQSEmployeesROEROAROCE
Lineage Cell Therapeutics Stock

Lineage Cell Therapeutics ROCE 2024

Lineage Cell Therapeutics ROCE

-0.39

Ticker

LCTX

ISIN

US53566P1093

WKN

A2PP89

In 2024, Lineage Cell Therapeutics's return on capital employed (ROCE) was -0.39, a 27.11% increase from the -0.31 ROCE in the previous year.

Lineage Cell Therapeutics Aktienanalyse

What does Lineage Cell Therapeutics do?

Lineage Cell Therapeutics Inc. is a biopharmaceutical company that focuses on the development and commercialization of cell therapies for various diseases. Originally established in 1990 as VisiGenics Inc., specializing in proteomic and genetic analysis, the company later changed its name to Lineage Cell Therapeutics Inc. to reflect its focus on the research and development of stem cell therapies. Lineage Cell Therapeutics develops and markets cell therapy products based on its own patents and discoveries, including therapies for eye, neurodegenerative, and cancer diseases. The company's proprietary technology platform gives it a crucial position in the field of cell therapy. Additionally, Lineage Cell Therapeutics collaborates with academic institutions and other biopharmaceutical companies to expedite the process of commercializing cell therapies. The company offers a wide range of cell therapies for various injuries and diseases, with key applications including: - OPC1: A cell-based therapy for spinal cord injuries caused by damage to the spinal cord. This therapy is being developed on the astrocyte differentiation treatment platform derived from embryonic stem cells (ES cells). - OpRegen: A cell-based regenerative product for dry age-related macular degeneration (tAMD). This therapy is based on the retinal pigment epithelium cell differentiation treatment platform derived from human embryonic stem cells. - VAC: An immunotherapy for cancer treatment. This treatment involves dendritic cells isolated from the patient's blood and genetically modified to present cancer-specific antigens. The goal is to stimulate the patient's immune system to trigger a specific immune response against cancer. Lineage Cell Therapeutics also pursues a strong expansion strategy. In 2020, it acquired a majority stake in AgeX Therapeutics, a biotechnology company focused on developing innovations in the field of stem cells. This acquisition strengthened the company's capacity for innovation and increased its ability to capitalize on future growth opportunities through partnerships, licensing, and product launches. Overall, Lineage Cell Therapeutics has become a significant player in the field of cell therapy, thanks to the use of cutting-edge technology and years of experience in the life science industry. One of the company's main goals is to develop and manufacture groundbreaking cell therapies to ultimately improve the lives of patients worldwide. Lineage Cell Therapeutics ist eines der beliebtesten Unternehmen auf Eulerpool.com.

ROCE Details

Unraveling Lineage Cell Therapeutics's Return on Capital Employed (ROCE)

Lineage Cell Therapeutics's Return on Capital Employed (ROCE) is a financial metric that measures the company's profitability and efficiency with respect to the capital employed. It is calculated by dividing earnings before interest and tax (EBIT) by the employed capital. A higher ROCE indicates that the company is effectively utilizing its capital to generate profits.

Year-to-Year Comparison

Analyzing Lineage Cell Therapeutics's ROCE annually provides valuable insights into its efficiency in using its capital to generate profits. An increasing ROCE indicates improved profitability and operational efficiency, whereas a decrease might signal potential issues in capital utilization or business operations.

Impact on Investments

Lineage Cell Therapeutics's ROCE is a critical factor for investors and analysts for evaluating the company’s efficiency and profitability. A higher ROCE can make the company an attractive investment, as it often signifies that the firm is generating adequate profits from its employed capital.

Interpreting ROCE Fluctuations

Changes in Lineage Cell Therapeutics’s ROCE are attributed to variations in EBIT or the capital employed. These fluctuations offer insights into the company’s operational efficiency, financial performance, and strategic financial management, assisting investors in making informed investment decisions.

Frequently Asked Questions about Lineage Cell Therapeutics stock

What is the ROCE (Return on Capital Employed) of Lineage Cell Therapeutics this year?

The ROCE of Lineage Cell Therapeutics is -0.39 undefined this year.

How has the ROCE (Return on Capital Employed) of Lineage Cell Therapeutics developed compared to the previous year?

The ROCE of Lineage Cell Therapeutics has increased by 27.11% increased compared to the previous year.

What does a high ROCE (Return on Capital Employed) mean for investors of Lineage Cell Therapeutics?

A high Return on Capital Employed (ROCE) indicates that Lineage Cell Therapeutics has efficient capital utilization and is able to achieve a higher return on its invested capital. This can be appealing to investors.

What does a low ROCE (Return on Capital Employed) mean for investors of Lineage Cell Therapeutics?

A low ROCE (Return on Capital Employed) can indicate that Lineage Cell Therapeutics has an inefficient utilization of its capital and may have difficulty in achieving a satisfactory return on its invested capital. This can be uncertain or unattractive for investors.

How does an increase in ROCE from Lineage Cell Therapeutics impact the company?

An increase in the ROCE of Lineage Cell Therapeutics can be an indicator of improved company efficiency and show that it is achieving higher profits in relation to its investments.

How does a reduction in the ROCE of Lineage Cell Therapeutics affect the company?

A decrease in ROCE of Lineage Cell Therapeutics can be an indicator of deteriorated efficiency of the company, indicating that it is generating lower profits in relation to its investments.

What are some factors that can influence the ROCE of Lineage Cell Therapeutics?

Some factors that can affect Lineage Cell Therapeutics's ROCE include efficiency in managing assets, profitability of investments, cost efficiency, and market conditions.

Why is the ROCE of Lineage Cell Therapeutics so important for investors?

The ROCE of Lineage Cell Therapeutics is important for investors as it is an indicator of the company's efficiency and shows how successful the company is in relation to its investments. A high ROCE can indicate strong financial performance of the company.

What strategic measures can Lineage Cell Therapeutics take to improve the ROCE?

To improve the ROCE, Lineage Cell Therapeutics can take measures such as increasing efficiency in asset management, optimizing investments, cost savings, and exploring new revenue sources. It is important for the company to conduct a thorough review of its operations to determine the best strategic actions to improve the ROCE.

How much dividend does Lineage Cell Therapeutics pay?

Over the past 12 months, Lineage Cell Therapeutics paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Lineage Cell Therapeutics is expected to pay a dividend of 0 USD.

What is the dividend yield of Lineage Cell Therapeutics?

The current dividend yield of Lineage Cell Therapeutics is .

When does Lineage Cell Therapeutics pay dividends?

Lineage Cell Therapeutics pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Lineage Cell Therapeutics?

Lineage Cell Therapeutics paid dividends every year for the past 0 years.

What is the dividend of Lineage Cell Therapeutics?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is Lineage Cell Therapeutics located?

Lineage Cell Therapeutics is assigned to the 'Health' sector.

Wann musste ich die Aktien von Lineage Cell Therapeutics kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Lineage Cell Therapeutics from 10/12/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 10/12/2024.

When did Lineage Cell Therapeutics pay the last dividend?

The last dividend was paid out on 10/12/2024.

What was the dividend of Lineage Cell Therapeutics in the year 2023?

In the year 2023, Lineage Cell Therapeutics distributed 0 USD as dividends.

In which currency does Lineage Cell Therapeutics pay out the dividend?

The dividends of Lineage Cell Therapeutics are distributed in USD.

Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.

Andere Kennzahlen von Lineage Cell Therapeutics

Our stock analysis for Lineage Cell Therapeutics Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Lineage Cell Therapeutics Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.